Alto Neuroscience, Inc. (ANRO) Free Cash Flow
Alto Neuroscience, Inc. (ANRO) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2022-12-31 | -$21.13M |
| 2023-12-31 | -$33.92M |
| 2024-12-31 | -$49.50M |
| 2025-12-31 | -$51.79M |
How ANRO compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| RLMD | Relmada Therapeutics Inc. | -$45.79M |
| ACRS | Aclaris Therapeutics Inc. | -$47.22M |
| ACHV | Achieve Life Sciences Inc. | -$49.47M |
| OSUR | OraSure Technologies Inc. | -$53.22M |
| PLSE | Pulse Biosciences Inc | -$54.46M |
These are five companies in the same sector as ANRO with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Alto Neuroscience, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("ANRO", 2025, "")
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | ANRO | $23.43 | -0.38% | 0.05M |
| 3 | ||||
| 4 | ||||
| 5 |